237435-43-7

Usage

Uses

Used in Pharmaceutical Research and Development:
1-(4-Chloro-2-methylpyrrolo[4,5-d]pyrimidin-6-yl)-4-methoxybenzene is utilized as a potential drug candidate for the treatment of various diseases. Its distinctive molecular structure and properties contribute to its promise as a target for medicinal chemistry studies, with the aim of identifying new therapeutic agents.
Used in Medicinal Chemistry Studies:
In the field of medicinal chemistry, 1-(4-Chloro-2-methylpyrrolo[4,5-d]pyrimidin-6-yl)-4-methoxybenzene serves as a valuable compound for research. Its synthesis and characterization have been the focus of scientific investigation, and ongoing studies are exploring its potential pharmacological activities to better understand its therapeutic potential.

Upstream product

• 237435-40-4 Toluene-4-sulfonic acid (Z)-2-cyano-1-(4-methoxy-phenyl)-vinyl ester 
• 237435-41-5 ethyl 3-amino-5-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate 
• 3672-47-7 3-oxo-3-(4'-methoxyphenyl)propanenitrile 
• 237435-42-6 6-(4-Methoxyphenyl)-2-methylpyrrolo[3,2-d]pyrimidine-4-ol 

Relevant academic research and scientific papers

Compounds and methods which modulate feeding behavior and related diseases

There are provided compounds, compositions and methods of use thereof in the modulation of feeding behavior, obesity, diabetes, cancer (tumor), inflammatory disorders, depression, stress related disorders, Alzheimer's disease and other disease conditions.

Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists

Neuropeptide Y (NPY) has been shown to play an important role in the regulation of food intake and energy balance. Pharmacological data suggests that the Y5 receptor subtype contributes to the effects of NPY on appetite, and therefore a Y5 antagonist might be a useful therapeutic agent for the treatment of obesity. In attempts to identify potential Y5 antagonists, a series of pyrrolo[3,2-d]pyrimidine derivatives was prepared and evaluated for their ability to bind to Y5 receptors in vitro. We report here the synthesis and initial structure-activity relationship investigations for this class of compounds. The target compounds were prepared by a variety of synthetic routes designed to modify both the substitution and the heterocyclic core of the pyrrolo[3,2-d]pyrimidine lead 1. In addition to identifying several potent Y5 antagonists for evaluation as potential antiobesity agents, a pharmacophore model for the human Y5 receptor is presented.